AbbVie Takes Amgen to Court Over 10 Humira Patents

AbbVie has filed a suit against Amgen accusing the drugmaker of infringing 10 patents protecting its blockbuster drug Humira.

The drugmaker contends Amgen’s biosimilar candidate ABP 501 infringes 61 of Humira’s patents, but the number in the suit was capped at 10 under the Biosimilar Price Competition and Innovation Act. ABP 501 received unanimous approval from an FDA advisory committee last month for five of Humira’s indications.

The patents cited in the dispute relate to the composition, production, formulation, indication, dosing and cell culture of Humira.